Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q1 2018 · 10-Q
Revenue—
Net Income-$739.39K-$739.39KN/M vs Q1 2017 EPS Diluted-$0.01-$0.01N/M vs Q1 2017 Operating Cash Flow-$321,841N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
ended Mar 31, 2018 · filed May 15, 2018 · 45 d after period end